Supernus Pharmaceuticals | SUPN - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.39B 27M 2026-03
ANI Pharmaceuticals USD 40.22M 8.74M 2026-03
Aurora Cannabis CAD 11.41M 12.99M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Canopy Growth CAD -157.96M 95.71M 2026-03
Cara Therapeutics USD -6.8M 1.9M 2026-03
Corcept Therapeutics USD -44.72M 54.62M 2026-03
Eisai JPY 25.28B 33.22B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Novo Nordisk DKK 33.8B 3.23B 2025-06
Pacira USD 5M 4.43M 2026-03
Perrigo USD 105.4M 513.9M 2026-06
Pfizer USD -653M 5.84B 2026-06
Supernus Pharmaceuticals USD -57.65M 51.7M 2026-06
United Therapeutics USD 372.7M 54.4M 2026-06
Xeris Pharmaceuticals USD 2.23M 8.85M 2026-03